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Abstract
The placenta supports the exchange of nutrients and gases between mother and
fetus. Trophoblasts are the parenchymal cells of the placenta and perform the vast
majority of its functions. There are different types of trophoblasts derived from stem cells
called cytotrophoblasts (CTs). The balance between CT proliferation and differentiation
is important for placental development. OVO-like 1 (OVOL1) is a transcription factor
expressed in many epithelial lineages undergoing differentiation, including human
differentiating CTs. The molecular mechanisms through which OVOL1 represses
proliferation and/or promotes differentiation are unknown. We hypothesize that OVOL1
interacts with specific HDACs to repress CT proliferation. Ectopically expressing
OVOL1 in wild-type yeast caused a significant growth defect, this defect was rescued by
deleting class II HDACs. Ectopically expressing OVOL1 in human CT cell-line (BeWo)
caused a significant increase in expression of ERVFRD1, a gene associated with
cytotrophoblast differentiation, indicating that expression of OVOL1 is sufficient to
trigger upregulation of at least a subset of genes that regulate CT proliferation and
differentiation. Together, our findings demonstrate that OVOL1 can repress cell
proliferation in yeast, a feature requiring specific HDACs, and is sufficient to at least
prime CT differentiation. The combination of yeast and mammalian models provides a
new experimental platform to better characterize OVOL1 function in repressing CT
differentiation, providing new insights into placental development and potential
therapeutics for placenta-associated diseases.

Keywords
OVOL1, HDACs, yeast, histones, BeWo, trophoblasts, cytotrophoblasts,
syncytiotrophoblasts, differentiation, proliferation.
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Summary for Lay Audience
During pregnancy, the placenta forms to facilitate the exchange of gases and
nutrients between the mother and baby. When abnormal placental development occurs,
complications can arise leading to serious harm to both the mother and baby. During the
initial stages of pregnancy, important steps have to take place to ensure proper placental
development. Formation of a specific placental cell-type that controls nutrient and gas
exchange is regulated by a protein known as OVO-like 1 (OVOL1). However, there is very
little known about how OVOL1 functions to form this important cell-type. Therefore, my
goal is to explore the underlying mechanisms by which OVOL1 acts and how it works to
trigger placental cells to undergo specialization and form different cell types. Therefore,
my main aim is to explore the underlying mechanisms by which OVOL1 acts. I will be
using yeast as a model organism to understand how OVOL1 affects gene expression. Yeast
are single-celled eukaryotic organisms that share many homologous genes with humans,
and allow us to conduct rapid, controlled experiments to identify how OVOL1 affects gene
regulation. I hope to identify gene and protein targets that can act as future therapeutic
targets to address placental maldevelopment. Future work will identify factors that affect
OVOL1 function in yeast and translate our findings into mammalian models. My findings
will provide insight into how the placental forms, which will help us better understand the
causes of various pregnancy complications.
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Chapter 1

1

Literature Review
1.1

Pregnancy Complications

According to Statistics Canada, in 2018, one of the main leading causes of infant and
maternal mortality and morbidity is maternal complications and diseases arising during
pregnancy. Complications during pregnancy can include pregnancy loss, stillbirth, and
hypertensive disorders1. 14% of maternal deaths are attributed to hypertensive disorders2.
When patients are diagnosed with chronic hypertension, they have a three-fold increased
risk of developing preeclampsia (PE) 3. PE is a condition characterized by hypertension
and protein in the urine (proteinuria) and affects close to 8% of pregnancies4. If serious
cases are not immediately treated, it can lead to severe complications during pregnancy,
delivery and postpartum. Over the last two decades, Auger et al. 5 found that the rate of
PE in Canada increased from 26 to 50 per 1000 deliveries, which was accompanied with
more intensive medical treatments. Furthermore, post-delivery, mothers diagnosed with
PE suffered complications such as increased blood-brain barrier permeability,
inflammation, hypertension, type 2 diabetes, acute and chronic vascular damage 6–9.
Siepmann et al. 10 found that there was a significant change in brain matter in women
with PE. Specifically, white matter volume increased while gray matter volume
decreased, and these structural impairments continued with time post-delivery. Removal
of the placenta, which terminates the pregnancy, remains the only viable treatment option
for serious PE cases; however, if this occurs prior to 37 weeks, severe neonatal
complications associated with prematurity can arise.
PE not only affects mothers, but it can also directly and indirectly cause
complications in the newborn. For example, PE is commonly associated with a serious
prenatal complication called intrauterine growth restriction (IUGR). IUGR can also occur
independently of preeclampsia. IUGR is a condition whereby the fetus is unable to reach
its full growth potential due to genetic or environmental causes 11. Babies diagnosed with
IUGR are more likely to be associated with pre-term onset of PE12, and have poor long
term health outcomes. Crispi et al.13 found that heart development in IUGR babies was
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disrupted. Babies had thicker cardiac walls leading to decreased stroke volume and
increased heart rate, all of which may increase risk of developing cardiovascular
complications later in life7,13–15.
PE and IUGR are often associated with poor development of the placenta. The
placenta is a vital organ necessary for maintaining a healthy pregnancy. Korteweg et al. 16
investigated the causes behind intrauterine fetal death after 20 weeks of pregnancy, and
found close to 67% out of 750 pregnancies were related to placental pathologies.
Similarly, Horn et al. 17 discovered that almost 60% of stillborn deliveries were
associated with utero-placental pathologies. Placental causes of death have been found in
up to 65% of perinatal mortality cases16. Pregnancies diagnosed with IUGR have smaller
placental volume with increased uterine vascular resistance 18. In addition, Ray et al.12
found an increase in placental insufficiency and vascular lesions with pregnancies
complicated with IUGR. Given the importance of proper placental formation for healthy
fetal development and pregnancy success, broadening our understanding behind
pathways, factors and mechanisms that regulate placental development is important to
help researchers develop more effective management strategies and therapies to reduce
the risks and outcomes associated with pregnancy diseases.

2

1.2

Regulation of Placental Development

The placenta is a vital organ that develops during pregnancy. This transient organ
regulates fetal growth by providing the growing embryo with adequate nutrients and
oxygen, removing metabolic waste products, acting as a barrier against xenobiotics found
in maternal circulation, and releasing hormones into both the maternal and fetal
circulation to regulate fetal growth and placental function throughout gestation 19,20.
Understanding how it forms will help us discern what goes wrong during conditions such
as PE and IUGR.
Formation of the placenta starts early during gestation. After the oocyte has been
fertilized, the resulting zygote undergoes multiple mitotic divisions to form a hollow
spherical structure known as the blastocyst. The blastocyst is made up of two important
cellular structures: the outer trophectoderm layer and an inner cell mass. The
trophectoderm gives rise to all trophoblast lineages that form the placenta. The inner cell
mass, on the other hand, develops into all other structures including the yolk sac and
embryo proper.
Approximately 7-8 days after fertilization, three important steps occur for the
blastocyst to implant into the endometrial wall. First, the embryonic pole of the
blastocyst made up of polar trophectoderm cells attaches to the uterine surface
epithelium. Second, trophectoderm cells express many adhesion and regulatory factors
such as integrins to allow for blastocyst adhesion. Lastly, a primitive syncytium that
differentiates from cytotrophoblasts in the polar trophectoderm releases enzymes that
break the endometrial wall and helps the blastocyst burrow deep into the decidua. Stem
cells in the trophectoderm differentiate into cytotrophoblasts, which proliferate
extensively to form primary villi. Cytotrophoblasts further differentiate into two cell
lineages: extravillous cytotrophoblasts and villous cytotrophoblasts. Extravillous
cytotrophoblasts form at the tips of the villi and differentiate into highly invasive cells
responsible for transforming maternal tissue and remodeling uterine arteries, thereby
improving blood flow to the placenta. Villous cytotrophoblasts serve as the progenitor
cells of the placenta throughout pregnancy. These cells are responsible for continuous
replenishment of a unique multinucleated lineage called syncytiotrophoblast that lines the
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placental exchange surface and forms the barrier separating maternal and fetal blood 21–26,
(Fig 1.1). Expression of syncytin genes like ERVW-1/ syncytin-1, ERVFRD-1/syncytin-2,
ERVV-1 and ERVV-2 is important to induce fusion of cytotrophoblasts into the
syncytiotrophoblast. Syncytin-1 and syncytin-2 are retroviral proteins only found in the
placenta and are important for cell fusion.
Fusion is regulated by a number of processes that act similarly in vesicle trafficking
and myocyte development. When fusion is induced, caspase 8 and 10 are activated which
act to deactivate flippases/translocase, this indirectly causes a change in which change
the location of negatively charged phospholipids known as phosphatidylserines from the
inner to the outer leaflet of the plasma membrane27,28. In addition, proteases are also
activated to remodel the cytoskeleton proteins and allow cells to come together and
maintain the syncytiotrophoblast layer28. Growth factors, such as epidermal growth
factor (EGF), are released by both the maternal and fetal environments29,30. EGF leads to
the release of human chorionic gonadotropin (hCG) from syncytiotrophoblast and acts in
a paracrine and autocrine fashion to induce cell fusion. They activate downstream
signalling molecules such as PKA to increase expression of genes expressing syncytial
proteins, syncytin 1 and syncytin 231,32. Syncytin proteins are retroviral proteins that bind
to amino acid transporters (ASCT1 and ASCT2) on the surface of plasma membrane to
help cells fuse26,33. Other proteins are expressed during fusion to aid in membrane
binding, like a disintegrin and a metalloproteinase domain (ADAM) protein family which
contain fusion peptides34.
In addition to forming the key barrier separating maternal and fetal blood, the
syncytiotrophoblast acts as an immunological barrier and produces hormones vital for
pregnancy. For instance, a characteristic of syncytiotrophoblast formation is an increase
in expression of transcripts important for hormonogenesis, such as CGA and CGB, genes
encoding the 𝛼 and 𝛽 subunits of hCG35.
The placental exchange surface is arranged in finger like projections to allow for
increase surface area and transfer of nutrient and oxygen. These projections are called
chorionic villi which protrude into cavities, known as intervillous space, filled with
maternal blood. The barrier is lined by syncytiotrophoblast, which faces the maternal
circulation, and underlying cytotrophoblasts which line the basement membrane 19,20.
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Importantly, cytotrophoblasts coordinately proliferate to maintain their stem cell
population, or differentiate (fuse) to maintain syncytiotrophoblast integrity 20.
Differentiation of cytotrophoblasts is crucial for syncytiotrophoblast to expand and
replenish, ensuring proper function of the exchange surface throughout pregnancy
19,20,36,37.

Fig 1.2 briefly summarizes the life cycle of cytotrophoblasts as they under

proliferation and differentiation. Abnormal cytotrophoblast proliferation or differentiation
can disrupt the integrity of the placental exchange surface and result in placental
pathologies, such as PE and IUGR, causing serious harm to mother and baby19,22,38–40.
Reconstitution of the syncytiotrophoblast is critical, since syncytiotrophoblast is
continuously dying and being shed into maternal blood. As the nuclei within the
syncytiotrophoblast age throughout gestation, they clump together at the surface of the
villous tree to form groups of aged nuclei known as syncytial knots, which become
apoptotic, and are shed into the maternal circulation 41. Disturbances to the process of
cytotrophoblast turnover may impair nutrient and gas exchange across the placental
barrier. Studies looking at placental tissues have revealed pathological changes of
preeclamptic and IUGR placentas compared to normal term placentas. Ezeigwe et al. 42
found that there was increase in cytotrophoblast proliferation. Arnholdt et al.43 also found
that this was accompanied by impaired syncytiotrophoblast formation when compared to
normal term placentas. Preeclamptic placentas had elevated expression of Ki-67 (a
proliferation marker) 44, increased activation of the ERK1/2 pathway (which promotes
cellular proliferation)45, and increased rate of apoptosis46. Furthermore, in PE and IUGR
placentas, there is an increased level of syncytial knots and apoptosis 47. The increase in
apoptotic shedding leads to the release of cell-free fetal DNA and protein into the
maternal circulation, resulting in inflammation. This process induces endothelial
dysfunction, which causes activation of the maternal immune response and leads to
maternal complications41,48. Dysregulation of villus trophoblast proliferation,
differentiation and turnover may be one possible explanation underlying inadequate
exchange of nutrients and aberrant placental development in IUGR and PE.
The regulation of cytotrophoblast proliferation and differentiation is not well
understood. The placenta is vulnerable to changes in the external (xenobiotics exposure)
and internal (maternal immune/inflammatory responses) environment, which may change
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expression of critical genes involved in cell proliferation and differentiation and
predispose to poor placental development in PE and IUGR 41,49. In order for the placenta
to respond to changes in its environment, cytotrophoblasts alter transcription of genes in
part through epigenetic regulation 19,50. Some studies report an increase in histone
acetylation in placental tissues from IUGR pregnancies, possibly because increased
acetylation alters the transcription profiles of genes related to normal placental
development, syncytiotrophoblast function and cytotrophoblast differentiation 51,52. The
regulation of genes promoting proliferation in trophoblasts is not well understood and
represents a major obstacle for understanding the underlying mechanisms governing
placental development. Our lab previously discovered that OVO-like 1 (OVOL1) is
highly upregulated during syncytiotrophoblast formation, and is critical for promoting
cytotrophoblast differentiation 35. Little is known about the underlying mechanisms of
OVOL1’s role in regulating trophoblast proliferation and differentiation, and thus will be
the focus of my thesis.
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Figure 1.1 Features of the chorionic villi that make up the maternal-fetal barrier.
The inner cytotrophoblast layer (blue cells) act as stem cells that undergo differentiation
and fusion to form the outer syncytiotrophoblast (pink cells). The syncytium is in direct
contact with the maternal blood which fills up the intervillous space.
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Figure 1.2 Summary of factors involved in trophoblast proliferation and
differentiation.
Proper turnover of placental trophoblast cells is necessary to maintain structure integrity
of the placental-maternal barrier. Depicted in this figure is a cross section of a chorionic
villus. Cytotrophoblasts can proliferate and maintain their stem cell population by
activating genes encoding proteins involved in fusion and hormonogenesis (1). In order
for differentiation to occur, the stem cell-associated genes are repressed, and genes that
promote fusion (ERVFRD-1) and hormonogenesis (CGB) are expressed to allow for cells
to form the overlaying syncytiotrophoblast (2). Lastly, aged nuclei cluster together at the
surface known as syncytial knots, which will be expelled into the maternal circulation
(3). (4) Functional HDACs are required for proper differentiation of cytotrophoblasts.
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1.3

OVO-Like Family of Proteins

OVOL1 is part of a conserved family of genes that encode C2H2 zinc finger “OVOlike” transcription factors. Currently there are 3 OVO-like genes, OVOL1, OVOL2 and
OVOL3 53–55. OVOL proteins were first characterized in Drosophila, they were
responsible for proper differentiation of the germline and oogenesis 56. They are also
expressed in epithelial and germ cell development in many organisms such as C. elegans,
D. melanogaster and M. musculus 56–59. OVOL1 plays an important role in epithelial cell
development across organisms and could be implicated in human diseases when the
balance between epithelial proliferation and differentiation is dysregulated.
Furue et al.60 conducted a meta-analysis genome wide association study and found
that OVOL1 was strongly associated with atopic dermatitis, a common skin disorder.
They discovered that OVOL1 works downstream of inflammatory markers in the skin,
and when it becomes inactivated, leads to skin barrier dysfunction which leads to
inflammation60. Jiang et al.61 also found that OVOL1 was implicated in nasopharyngeal
carcinoma by repressing proteins involved in angiogenesis and tumorigenesis. Similarly,
work done by Tsuji et al. 62 revealed that OVOL1 controls expression of skin barrier
proteins in human keratinocytes62. OVOL1 is upregulated in cutaneous squamous cell
carcinoma (CSCC) and decreases in expression as cells shift into a more invasive state63.
OVOL1 works by repressing c-Myc expression to prevent CSCC from becoming
invasive63. OVOL1 regulates interfollicular epidermal development by binding to the
promoter of c-Myc, repressing its transcription and activating differentiation64.Similarly,
OVOL2 also represses c-Myc expression thereby inhibiting terminal differentiation in
human keratinocytes 65. OVOL1 also works with OVOL2 in human hair bulb cell
proliferation and differentiation63. Ito et al.54 and Teng et al.66 discovered that OVOL1
was able to downregulate OVOL2 expression in human keratinocytes, suggesting
OVOL2 to be a downstream target of OVOL1. They also showed that OVOL1 is critical
for keratinocyte terminal differentiation while OVOL2 suppresses differentiation.
OVOL1 expression is important in other epithelial cell lineages, upregulation of OVOL1
inhibits oral squamous cell carcinoma proliferation by repressing ZEB1 (a transcription
factor) to prevent metastasis67.
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Ablation of OVOL1 in mice results in skin progenitor cells proliferating abnormally
leading to aberrant skin development and mammary gland branching 57,68–70. Somatic
cells of mouse embryonic fibroblast can undergo reprogramming to become induced
pluripotent stem cells (iPSCs); however, some cells fail to transition, this is where
OVOL1 was discovered to repress cellular proliferation and expansion71. Keratinocytes
derived from OVOL1 ablated mice showed increase cell proliferation, and mice showed
increase skin permeability when either OVOL1 or OVOL1 and OVOL2 were knocked
out66. OVOL1 also plays a role in osteogenesis, Min et al.72 found that by ectopically
expressing OVOL1 in mice, it enhanced expression of osteogenic genes which allowed
for osteoblast differentiation in mice and an increase in expression of osteoblast
differentiation markers such as Id2. OVOL1 and OVOL2 work together to inhibit
epithelial-to-mesenchymal transition (EMT) in certain epithelial tissues and cancer cell
lines 69,73. In contrast, in mice prostate cancer cells, OVOL1 and OVOL2 induce a
mesenchymal to epithelial transition (MET) 73. Murata et al. 74 found that ZEB1
expression was higher in tumors with low OVOL2 expression. Both OVOL1 and OVOL2
affect ZEB1 expression, OVOL2 directly downregulates ZEB1 expression while OVOL1
indirectly decreases ZEB1 transcript levels74. This regulation is important because it is
believed to prevent the development of CSCC74. Lastly, OVOL1 promotes pancreatic
stem cell differentiation into endocrine cells75. OVOL1 protein levels increases in
pancreatic differentiated cells, which suggests that OVOL1 promotes cells to achieve a
more differentiated state in pancreatic tissues of mice75.
The OVOL family of proteins play important roles in epithelial development. Mouse
OVOL2 is important for cranial tube development, and deletion of OVOL2 in mice
causes severe defects during cranial neural tube formation which leads to embryos
mortality. OVOL2 induces neuroectodermal differentiate, and is necessary for proper
brain, neural crest, gut tube and heart development in mice76. It is also critical in testis
development, brain, and epithelial development in the skin and intestine of adult mice77.
However, postnatal germ cell development and spermatogenesis is regulated by OVOL1
and not OVOL2 in mice78. Unezaki et al. 58 found that OVOL2 was important during
vascular angiogenesis during early embryogenesis, and trophoblast differentiation;
embryos abnormally develop and are small in the absence of OVOL258.
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Interestingly, in different cell types, OVOL1 functions as a gene repressor, and in
certain cases it repress genes downstream of Wnt/ 𝛽-catenin and BMP/TGF-𝛽 signaling
pathways23,77,79,80. Wnt signaling is also important in placental development in mice and
humans 80–82. Wang et al.83 found that expression levels of signalling molecules like Wnt
and 𝛽-catenin were upregulated in PE.
OVOL1 is expressed in skin, kidney and male germinal epithelium 57, and is able to
repress OVOL1 expression and downstream targets by binding to a core hexamer
sequence, CCGTTA, within the promoter regions of genes such as c-Myc and Id2 64,84–86.
Nair et al.84 found that OVOL1 binds to its own promoter by competing with c-Myb
(proto-oncoprotein) and represses its own transcription. OVOL1 transcript levels are
restored in the absence of a functional OVOL1 protein, and with increased expression of
c-Myb. However, little is known about the role of OVOL1 during trophoblast
proliferation and differentiation. Since OVOL1 acts to repress proto-oncoproteins and
genes critical for cell proliferation, we postulate that OVOL1 may similarly control
cytotrophoblast proliferation. Nair et al.64 found that OVOL1 was important in mice
interfollicular epidermal differentiation, in the absence of OVOL1 the progenitor cell
layer in the epidermis of adult mice was expanded. Without OVOL1, the epidermal
progenitor cells fail to stop proliferating, even in response of extrinsic growth inhibitory
signals like LiCl, TGF-beta and Ca2+ .
DNA microarray analysis conducted by Renaud et al. 35 revealed that OVOL1 was
the most highly unregulated transcript encoding a transcription factor in differentiating
BeWo cells – a choriocarcinoma cell line that is commonly used as a model of
cytotrophoblast differentiation. Knockdown of OVOL1 impaired the capacity of these
cells to fuse. When BeWo cells were induced to differentiate using 8-Bromo-cAMP,
there was a dose dependent increase in OVOL1 transcript levels35. Furthermore, OVOL1
expression is high when primary cytotrophoblasts spontaneously fuse; however, OVOL1
levels decrease once syncytiotrophoblast forms 35. Knockdown of OVOL1 in BeWo cells
correlated with a decrease in the ability of these cells to fuse. They also performed RNAseq analysis and found that genes encoding proteins associated with syncytiotrophoblast
hormonogenesis such as CGA, CGB, HSD3B1, and CYP19A1 were downregulated in
OVOL1-deficient cells. Syncytin genes (ERVW-1/ syncytin-1, ERVFRD-1/syncytin-2,
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ERVV-1 and ERVV-2) are endogenous retroviral derived genes which drive cell fusion. In
the absence of OVOL1, there was a markedly decreased expression of these syncytin
genes 35.
How OVOL1 is able to control cytotrophoblast differentiation is still unclear. OVOL1
directly binds upstream of several genes implicated in cytotrophoblast proliferation –
MYC, ID1, TP63 and ASCL2 – by binding to CCGTTA sequences located in the proximal
promoter regions of those genes, suggesting that OVOL1 is able to regulate expression of
genes important for proliferation35. Further, OVOL1 does not seem to activate fusogenic
genes such as ERVFRD-135. Whether OVOL1 recruits co-repressors or forms a complex
of transcription factors to downregulate genes involved in proliferation is unclear, and
understanding the underlying mechanisms governing OVOL1’s action will be the focus
of this thesis. To delineate the importance of specific domains of OVOL1 in causing
growth arrest in yeast, we used two mutated versions of OVOL1. Nair et al.84 discovered
that mutating the cysteines to alanines in the first three zinc finger motifs of OVOL1
disrupted OVOL1-DNA binding and proper zinc finger formation inhibited the capacity
of OVOL1 to exert transcriptional repression. Thus, we wanted to use a similar strategy
to determine whether the decrease in yeast growth is due to OVOL1 binding to DNA
through its zinc finger domains. Three different forms of OVOL1 will be used to study its
function in cell growth and proliferation summarized in Fig 1.3: wild type OVOL1,
SNAG-deleted OVOL1 (Δ15 OVOL1), and zinc-finger mutated OVOL1 (ZnFC2A).
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Figure 1.3 OVOL1 protein structures and mutations used in this thesis.
OVOL1 contains two conserved domains, the SNAG domain responsible for binding
onto histone deacetylase proteins, and four zinc-finger domains responsible for DNA
binding. ZnFC2A- OVOL1 mutation is produced by mutating the first two zinc finger
binding domains from cysteines to alanines, and the addition of an alanine in the third
zinc finger region. Δ15-OVOL1 is produced by deleting the first 15 amino acids which
includes the SNAG domain.
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1.4

Histone Deacetylases and the Placenta

Epigenetic modifications are essential in regulating proliferation and differentiation
of all stem cell lineages, and aberrant gene regulation caused by perturbations in
epigenetic modifications has been documented in a number of diseases such as cancers,
neurodegenerative diseases, and placental diseases 20,50,87–92. Gene expression can be
regulated using diverse mechanisms including DNA methylation, non-coding RNA or
through post-translational modifications of histones 93,94. Histones are crucial proteins
responsible for packaging the long strands of DNA into a more condensed structure
known as chromatin. Two copies of each histone proteins H2A, H2B, H3 and H4
assemble together to form an octameric complex to allow for the DNA to wrap around.
Post-translational modifications can occur on histone N-terminal tails through
methylation and acetylation to regulate the packaging density of DNA 90,95. Histone
posttranslational modifications include methylation, sumoylation, phosphorylation, and
acetylation 95–97. Our lab recently showed a key role for histone (de)acetylation during
cytotrophoblast differentiation 98. Therefore, our work focuses primarily on
understanding how pathways that regulate acetylation affects cellular proliferation in
placental development. Acetylation is a dynamic process regulated by both histone
acetyltransferases (HATs) and histone deacetylases (HDAC). HATs and HDACs act in
opposition to each other, HATs add acetyl groups to 𝜀-lysine residues on the N-terminal
tails of histones and non-histone proteins, while HDACs remove acetyl moieties 92,99.
Acetyl groups act to neutralize the positive charge on histone complexes, which allows
the DNA to be in a more relaxed state. Conversely, HDACs remodel chromatin into a
more condensed state, preventing transcription factors from accessing DNA thereby
repressing gene expression92,95,97,100–104. Fig 1.4 provides a summary of how HDACs are
able to remodel the chromatin. Generally, hyperacetylation of histones leads to gene
expression, while hypoacetylation results in gene repression 101,102,105. Transcriptional
dysregulation can lead to abnormalities in cell proliferation and differentiation; aberrant
recruitment of HDACs has been linked to cancer, neurodegenerative disorders, and
pregnancy-related disorders such as PE and IUGR 36,87,101,106–109. HDACs do not directly
bind to DNA, and therefore must operate in multiprotein complexes to modify both
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histones and proteins 110. Multiprotein complexes acts as corepressors and include the
interaction of HDACs with Sin3, nucleosome remodeling and histone deacetylation
(NuRD) and CoREST 110–112. HDACs also regulate acetylation on non-histone proteins,
like p53 and 𝛼-tubulin, to regulate cellular functions such as RNA processing, cellular
metabolism, and apoptosis 113–115.
HDACs fall into two protein families: NAD+-dependent and Zn2+-dependent. The
Zn2+-dependent HDACs are further subdivided into three classes (class I, II, and IV). The
NAD+-dependent HDACs comprise class III HDACs.99,101,102,104,116. HDACs are highly
conserved among eukaryotes. For example, class I HDACs are closely related to the yeast
histone deacetylase, RPD3; class II is linked to yeast HDA1; and class III linked to yeast
SIR2 101–104. Some of these HDACs localize exclusively to the nucleus and others shuttle
between the nucleus and the cytoplasm 101,102,104. The interplay between function and
localization of HDACs is important to regulate genes involved in cellular proliferation.
HDAC inhibitors have been widely studied as therapeutic targets to treat proliferating
cancer cells 117.
HDAC1 and a subunit of the NuRD complex binds to genes implicated in embryonic
stem cell pluripotency, including Oct4 and Nanog, causing transcriptional repression of
these genes 118. Furthermore, HDAC inhibitors such as trichostatin A (TSA) have been
used to delineate the roles of HDAC function in embryonic stem cell function117,119.
Kidder and Palmer118 conducted a transcriptome analysis mouse trophoblast cells treated
with TSA revealed that HDAC1 was able to bind to stem-cell associated genes enriched
in trophoblast cells such as Cdx2, Elf5, Eomes and Sox2 – all of which prevent
trophoblast lineage differentiation. The blastocyst has two stem cell lineages, embryonic
stem cells and trophoblast stem cells, and during implantation two molecules are released
to allow for each cell population to self-renew. In mice trophectoderm development,
HDAC1 binds to promoter regions of genes like LIF and FGF4, involved in the
stimulating the inner cell mass to proliferate and in trophoblast self-renewal, respectively
118.

HDAC1 can interact with BRG1, a chromatin remodelling protein, to coregulate a
number of genes involved in mouse embryonic stem cell development120. In addition,
HDAC1 is able to bind to cell-cycle proteins such as cyclin-dependent kinases (such as
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Cdk4), and cyclin-dependent kinase inhibitors (Cdkn1a/b), c-Myc, and p53 to regulate
cell cycle progression and tumorigenesis in trophoblast cells120.
Jaju et al.98 found that treating cytotrophoblast cells with TSA reduced differentiation
potential of BeWo trophoblasts. This was correlated with TSA-dosage dependent
increase in acetylation of the following: histone 2B-lysine site 5 (H2BK5), histone 3lysine site 27 (H3K27) and 14 (H3K14). These results suggest that deacetylation is an
important mechanism involved in syncytialization. Interestingly, HDAC1 and HDAC2
were found to be critical in trophoblast cell fusion. HDAC1 and HDAC2 have similar and
distinct biological functions. For example, there is no phenotypic changes in tissues such
as smooth muscle, epidermis and cardiomyocytes when HDAC1 or 2 are ablated,
suggesting that these HDACs can compensate for each other121–123. However, a double
knockout of HDAC1 and 2 results in severe defects in these tissues124. Similar to other
tissues, Jaju et al.98 found that the knockdown of either HDAC1 or HDAC2 did not affect
cytotrophoblast differentiation; however, upon ablating both, cytotrophoblasts ceased to
differentiate.
As described thus far, HDAC function and regulation of gene expression is crucial for
proper trophoblast proliferation and differentiation. Whether HDACs and OVOL1
function cooperatively to regulate cytotrophoblast cells is not known. Nair et al.84
discovered that when overexpressing OVOL1 and HDAC1 in H293 cells, OVOL1 was
able to bind to HDAC1 through its N-terminal SNAG transactivation domain. The SNAG
region is a conserved region found in other zinc finger transcriptional repressors, such as
Snail1 and Snail2, transcription factors involved in EMT induction125. Snail proteins are
able to recruit chromatin remodelling complexes consisting of HDAC1 and HDAC2
125,126.

These Snail-proteins interact with NCoR within the HDAC1 complex125. Deletion

of the first 15-amino acids which includes the SNAG domain and mutation in the zinc
finger region of OVOL1 disrupts the ability of OVOL1 to repress gene expression84.
When Nair et al. 84 co-expressed OVOL1 and HDAC1, there was enhanced repression of
OVOL1. In addition, OVOL1 decreases acetylation of histone 3 (H3) on the OVOL1
promoter. When the OVOL1 zinc finger region is mutated or when OVOL1 displaces cMyb binding, it causes a decrease in acetylation of H3, which strongly suggests that
OVOL1 mediates transcriptional repression by deacetylating histones near target genes. It

16

is currently unclear whether there is a genetic interaction between OVOL1 and HDACs.
To study the nature of the relationship between OVOL1 and HDACs in cellular
proliferation, I will employ a combination of human trophoblast model and the budding
yeast Saccharomyces cerevisiae, that recapitulates many of the features of the human
transcriptional regulation, including histone acetylation.
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Figure 1.4 Histone posttranslational modifications alter chromatin structure.
DNA wraps around an octamer of histone proteins that form a nucleosome. Histones have
an N-terminal tail that is post-translationally modified to regulate gene expression.
HDACs remove acetyl groups while HATs add acetyl groups to lysine on histone tails.
The acetyl moiety acts to neutralize the positive charge on the histone proteins, which
relaxes chromatin structure and allowing for transcription factor accessibility.
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1.5

Yeast as Model Organism to Study Transcriptional

Regulation
Studying transcriptional regulation, protein interaction and overexpression is difficult
in mammalian cultures due to the complexity of its signalling pathways. Yeast
Saccharomyces cerevisiae offer researchers a simple cellular model to study signaling
pathways and protein interactions. It has a high degree of conserved cellular processes
and mechanisms with higher level eukaryotes such as humans, including processes that
regulate cell division, gene expression, cell death, metabolism, DNA repair protein
folding and degradation 115,127–131. Many tools exploring gene expression and conserved
protein interaction networks were first developed and validated using a yeast model 132.
Yeast are easy to genetically manipulate, harvest and perform genome wide screens due
to the availability of a plethora of gene deletion libraries 133,134.
The discovery of histone function and its protein interactions were first identified in
yeast. There are two pairs of conserved genes encoding the four histone proteins that
make up the nucleosome, two genes encoding H2A and H2B, and the other two encoding
H3 and H4. Studies that used yeast as a model were first to demonstrate that a mutation in
both HTB1 and HTB2, encoding histone H2B, produce inviable cells135. Nucleosomes
will compact the DNA into a chromatin structure that can be remodelled when histones
are post-translationally modified. Early studies looking at gene repression was
demonstrated in yeast looking at PHO5 (acid phosphatase) promoter activity under high
phosphate environment which would suppress PHO5 activity by altering histone
expression levels 136. When histone H4 expression was reduced, the PHO5 promoter
became activated. Studies on phosphate regulated genes like PHO5, PHO2, and PHO4
helped establish our knowledge surrounding nucleosome function in remodelling
chromatin and preventing transcription factors from accessing promoters 136.
Interaction networks established a conserved link between humans and yeast, and showed
that chromatin structure is controlled by conserved factors 137–140. Yeast proteomics and
gene expression data has been applied to data on humans and other model organisms 141–
145.
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Given the complexity of epigenetic regulation, the yeast model provides us with a
relatively small number of proteins implicated in epigenetic regulation. For instance,
yeast only rely on histone modifications to change epigenetic states, which simplifies
studying epigenetic markers94. Therefore, yeast make an excellent model organism to
study the interplay between transcription factors, histone deacetylases and their effect on
cell growth and proliferation. Much of our understanding of transcriptional regulation in
eukaryotic cells comes from yeast studies. Many factors are highly conserved, such as the
human and yeast TATA-box binding proteins (TBP), which share 80% identity and are
functionally conserved. Either human or yeast TBP can be used for transcription by RNA
polymerase II. Moorefield et al. 146 expressed human RNA polymerase I, encoded by the
human RRN3 gene, in yeast cells possessing a non-functional RRN3 gene, and it was able
to rescue a severe viability defect.
Human proteins involved in regulating cell cycle control are also conserved in yeast.
Yeast only express one heat shock factor (HSF), which differs from humans, and the
human HSF1 functionally complements the HSF found in yeast. Similar to the RRN3
experiment described above, heterologous expression of the human HSF1 gene rescued a
growth defect in yeast with HSF deletion 147. Aberrant cell cycle control can lead to
cancer and tumorigenesis. Both tumor and yeast cells share similar metabolic pathways.
The RAS subfamily of proteins are highly conserved between humans and yeast, yeast
express Ras1 and Ras2 proteins regulating the cAMP/PKA signalling pathway148,149.
Yeast RasV119 protein which is homologous to human RasV12 (encoded by an
oncogene) was heavily studied in yeast, and was discovered to increase mitochondrial
metabolism which is important during tumorigenesis 148,149. PI3K/AKT pathways is also
heavily conserved in yeast, yeast encode SCH9 which is homologous to human Akt1
important in coordinating cell metabolism and the TOR signalling pathway148–150. When
yeast are in a carbon rich media, they prefer to use a process known as fermentation
instead of oxidative metabolism151. Glucose is able to repress oxidative metabolism in
yeast, and this is similar in tumor cells. This process is regulated by human Akt and yeast
Sch9 protein, all involved in TOR signalling pathway151..
Furthermore, heterologous expression of human genes implicated in cancer
progression, such as p53, BRCA1 and BRCA2 in yeast helped pave our understanding of
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not only tumorigenesis, but also cell cycle regulation, protein synthesis, autophagy, and
proteasome activity – all pathways highly conserved in yeast 113,152,153. Functional
analysis of p53 mutations have led to the discovery of target genes in yeast, and were
found to induce apoptotic-like cell death in yeast 153. Tumor suppressor genes like
BRCA1 and BRCA2 have also been successfully expressed and studied in yeast;
expression of BRCA1 causes cell growth arrest and phenotypic changes in yeast 153,154.
Yeast have been used extensively to investigate epigenetic regulation, chromatin
remodeling and cellular proliferation. Importantly, HDAC protein sequences are highly
conserved across eukaryotes including yeast (Table 1.1). Duffy et al 155 used the yeast
acetylome to investigate the functional differences between different HDACs. They
found that yeast HDACs that work in complexes, like Sin3-Rpd3 complex and HAD
complex, have similar and distinct interaction profiles. There are 327 unique interactions
found in the class II family of HDACs, where only 7% of those interactions were shared
among each subunit and 55% were specific to each HDA1, HDA2, and HDA3 proteins.
Interestingly, the HAD complex is important in peroxisome translation, but HDA2
protein is only involved in regulating peroxisome biogenesis. HDACs can also
deacetylate non-histone proteins, and many human proteins that are acetylated have yeast
homologs156. Acetylation can affect protein activity, stability, interaction and localization.
In a yeast RPD3 deletion screen, Duffy et al. 155 found that 4 out of the 187 proteins
tested had a defect in localization which were membrane proteins, ubiquitin domaincontaining protein – UBX3, and receptors important in drug and ion transport.
Functional assays like genome wide screens and growth assays can be used in
yeast to determine targets and effects of heterologous expressed genes in cell cycle
regulation and growth. HDACs and OVOL1 are both implicated in cellular proliferation
in cytotrophoblasts, and whether there is a genetic interaction between them is unknown.
There is no known yeast homolog of human OVOL1, and this is important because it
allows us to explore OVOL1 in a genome uncomplicated by other pathways involved in
human cell proliferation. By using the highly conserved yeast genome, we can better
delineate interaction networks of OVOL1.
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Table 1.1 HDAC Classes Conserved between Yeast and Humans.
HDAC proteins are highly conserved across eukaryotic organisms and are grouped based
on sequence similarities 99,102.
Class

Saccharomyces cerevisiae

Homo sapiens

I

Rpd3

HDAC 1, 2, 3, 8

Hos1
Hos2
Hos3
II

Hda1

HDAC4, 5, 6, 7, 9a, 9b, 9c,

Hda2

10

Hda3
III

Sir2

Sir1, 2, 3, 4, 5, 6, 7

Hst1
Hst2
Hst3
Hst4
IV

(Not found in yeast)

HDAC11 (has been
characterized to have both
class I and II functions)

22

1.6

Hypothesis

How Ovol1 is able to bind to DNA and regulate gene expression during cell division
and differentiation is not well understood. Therefore, understanding the underlying
mechanisms of gene regulation by OVOL1 will further elucidate components of placental
biology as well as organ development. Recently, Bhattad et al. 2020 found that HDAC1
and HDAC2 are necessary for cytotrophoblast differentiation. Therefore, I hypothesize
that OVOL1-dependent regulation of gene expression requires HDACs to regulate
cellular proliferation.

1.7

Objectives

My project employs a combination of two cellular models: the budding yeast
Saccharomyces cerevisiae and human BeWo cytotrophoblast-like cells. Due to the high
level of conservation in cellular pathways and transcriptional regulation between yeast
and humans, yeast is a valuable tool to study novel transcription factors and their role in
gene regulation. Therefore, my primary objective is to study the effect of OVOL1
expression on cell growth in yeast and test the importance of HDACs for OVOL1mediated effects.
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Characterizing the Role of OVOL1 in Cell Growth

2

Regulation
2.1
2.1.1

Materials and Methods
Cell Strains and Media Conditions

Saccharomyces cerevisiae yeast strains used are summarized in Table 2.1. All
strains used are derivatives of BY4742. Yeast cells are thawed from frozen glycerol
stocks onto YPD (yeast extract peptone dextrose) plates for two days at 30°C. All yeast
cells were cultured into selective synthetic complete media containing 2% w/v glucose
and incubated at 30°C overnight. In order to induce expression of OVOL1, cells are
washed twice in media containing 2% w/v galactose and resuspended at optical density
(OD600nm) 0.2 and incubated overnight at 30°C in galactose containing media.
Human BeWo trophoblast-like cells, which are derived from choriocarcinoma and
are a well-established model of cytotrophoblast-like cells (ATCC CCL-98) were thawed
from frozen stocks into DMEM: F12K media supplemented with 10% Fetal Bovine
Serum (FBS) and 0.5% Penicillin/Streptomycin (P/S). Cells are passaged at 30%
confluency into 24-well plates for transfections.

34

Table 2.1 List of Yeast Strains.
Yeast Strains

Genotype

Reference

BY4742

MATα his3Δ1 leu2Δ0 lys2Δ0

1

ura3Δ0
hda1Δ

Same as BY4742 except
HDA1::KAN

hda2Δ

Same as BY4742 except
HDA2::KAN

hda3Δ

Same as BY4742 except
HDA3::KAN

rpd3Δ

Same as BY4742 except
RPD3::KAN

hos1Δ

Same as BY4742 except
HOS1::KAN

hos2Δ

Same as BY4742 except
HOS2::KAN

hos3Δ

Same as BY4742 except
HOS3::KAN

sir2Δ

Same as BY4742 except
SIR2::KAN

hst1Δ

Same as BY4742 except
HST1::KAN

hst2Δ

Same as BY4742 except
HST2::KAN

hst3Δ

Same as BY4742 except
HST3::KAN

hst4Δ

Same as BY4742 except
HST4::KAN
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Deletion array

2.1.2

Plasmid Construction
OVOL1, ZnFC2A, and Δ15-OVOL1 were synthetized by Thermo Fisher

Scientific. Using polymerase chain reaction (PCR), OVOL1 fragments were generated
and cloned into p415-gal1 and p416-gal1 plasmids using SpeI/SalI restriction enzymes.
Plasmids were validated by sequencing them at Robarts Sequencing Facility (London
ON). All plasmid constructs are listed in Table 2.2 for yeast plasmids and 2.3 for
mammalian plasmids.

Table 2.2 List of Yeast Plasmids.
Plasmids

Vector Backbone

Resistance

Reference

GAL1-OVOL1

pRS415

Leu+

This paper.

GAL1-ZnFC2A

(CEN/ARS)

GAL1-Δ15OVOL1
OVOL1-ymsfGFP
GAL1-OVOL1

pRS416

GAL1-ZnFC2A

(CymEN/ARS)

Ura+

GAL1-Δ15OVOL1
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Table 2.3 Mammalian Plasmids.
Plasmid

Vector Backbone

Reference

pEF-GFP

pCAGEN

Addgene (#11154)

pEF-OVOL1

2.1.3

This paper.

Yeast Transformation
Plasmids were transformed into yeast strains (listed in Table 2.4) using a high-

efficiency lithium acetate protocol described in Gietz et al.157. In brief, cells were cultured
overnight, and cells at OD600nm of 1.0 were pelleted at 3000  g for one minute in a 1.5
mL Eppendorf tube. Cells were then washed and incubated for five minutes at room
temperate using 1.5 mL of sterile 0.1 M Lithium Acetate (LiAc) in Tris and EDTA (TE)
Buffer. Cells were then resuspended in 285 µL sterile 50% PEG, 2.5 µL plasmid and 10
µL boiled salmon sperm DNA. Cells were incubated at 30°C for 45 minutes. Following
incubation, 43 µL of sterile DMSO was added to cells and heat shocked at 42°C for 15
minutes. Cells were then plated onto selection agar plates.

2.1.4

Growth Assays
Cells were grown in glucose overnight then subsequently washed and incubated

in galactose media (refer to section 2.1.1). They were then serially diluted five times at
OD600nm 0.2 in a 96-well plate and spotted onto agar plates. Plates were incubated for two
nights and imaged using a Bio-Rad Laboratories GelDoc System.
Liquid growth assays were conducted using the same cells that were spotted onto
agar plates. Using a clear 96-well plate, diluted cells were replicated 3 times, and OD600nm
was measured every 15 minutes for 24 hours using a Biotek plate reader.

2.1.5

Fluorescent Microscopy
WT and hda1Δ cells expressing OVOL1ymsfGFP were induced in galactose

media as described in 2.1.1. Cells were diluted 10X, transferred into a 6-well plate, and

37

imaged at room temperature using Cytation 5 Cell Imaging Multi-Mode Reader (BioTek)
with a 20X objective lens and EGFP filter (488-509 nm). Images were analyzed using
ImageJ software (https://imagej.nih.gov/ij/).

2.1.6

BeWo Trophoblast Cell Transfection
BeWo cells were split into 24-well plates at around 30% confluency. The

following day, media were changed, and transfection was conducted according to
JetPrime DNA transfection protocol (https://www.polyplustransfection.com/products/jetprime/). Briefly, BeWo cells were transfected with plasmids
found in Table 3. In brief, 1.5 µg of DNA was diluted into 200 µL JetPrime Buffer and
vortexed for 10 seconds. 3 µL of JetPrime reagent was added, vortexed for one second,
and incubated at room temperature for 10 minutes. 200 µL of the mixture was added into
each well in a drop-wise manner. Two sets of controls were used, one well had a regular
media change (non-transfected), while the other control was transfected with the vector
backbone. BeWo cells were also induced to differentiate for 48 hours (hrs) using 10
µL/ng of cell-permeable derivative of 3′, 5′-cyclic adenosine monophosphate (cAMP).

2.1.7

Quantitative RT-PCR
RNA was extracted using MasterPure Yeast RNA Purification Kit (Epicentre).

RevertAid H Minus First Strand cNDA Synthesis Kit (Thermoscientific) was used to
synthesize cDNA. SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) was used
to amplify cDNA. Primers used are listed in Table 4. Yeast control primer is U3; control
primers for experiments using BeWo cells are 18s and EEF2. For trophoblast RNA
extraction, we used a protocol previously described in3. In brief, RNA was extracted
using Ribozol (VWR International), following manufacturer’s protocol. cDNA was
created using High Capacity cDNA kit (ThermoFisher Scientific) and Sensifast SYBR
Green PCR Master Mix (FroggaBio). cDNA samples were diluted 10X and quantitative
PCR was performed using OVOL1, CGB, ERVFD-1 primers (Table 2.4); fluorescence
was detected using a CFX96 Connect real-time PCR detection system (Bio-Rad
Laboratories). Relative mRNA expression was calculated using the comparative Ct
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method using the comparative mean of reference genes: 18 S Ribosomal RNA
(RNA18SN1) and Eukaryotic Elongation Factor 2 (EEF2) for BeWo cells, and U3 (for
yeast cells). Reference genes were chosen because they have relatively consistent
expression levels across cells and experimental conditions.

Table 2.4 List of Primers.
Primers

Sequences

OVOL1/ ZnFC2A/

F: CCGTGCGTCTCCACGTGCAA

Δ15OVOL1

R: GGCTGTGGTGGGCAGAAGCC

U3

F: CCCAGAGTGAGAAACCGAAA
R:AGGATGGGTCAAGATCATCG

CGB

F: CCTGGCCTTGTCTACCTCTT
R:GGCTTTATACCTCGGGGTTG

ERVFD-1

F: CCAAATTCCCTCCTCTCCTC
R: CGGGTGTTAGTTTGCTTGGT

TP63

F: CAGATGGACCTGACCAAACC
R: AGCTCCGCATCAGCAACTAC

RNA18SN1

F: GCAATTATTCCCCATGAACG
R: GGCCTCACTAAACCATCCAA

EEF2

F: AGGCGTAGAACCGACCTTTG
R: GACAGCGAGGACAAGGACAA

2.1.8

Yeast Protein Extraction
Cells were incubated overnight in galactose media to induce expression of

OVOL1 and then were lysed using the following lysis buffer: 100mM Tris pH 7.5,
200mM NaCl, 1 mM EDTA, 5% glycerol, 1mM Dithiothreitol (DTT).

2.1.9

Mammalian Cell Protein Lysis
Cells were washed with cold phosphate-buffered saline (PBS) and incubated at

room temperature with 100 µL of RIPA buffer with protease inhibitor cocktail diluted
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1:100 for 10 minutes with shaking. Cells were then scraped off using a cold pipette tip
and transferred into a microcentrifuge tube. Cells were lysed using a 27-gauge syringe
several times. Samples were pelleted for five minutes at 14 000 rpm. Supernatant was
transferred into a new microcentrifuge tube and frozen at -20°C.

2.1.10

Western Blot Analysis

Protein samples were separated using SDS-PAGE (BioRad Mini-PROTEAN
TGX Pre-Cast gels, 4-15%) and transferred to nitrocellulose membranes using BioRad
Trans-Blot Turbo RTA Transfer Kit. Membranes were blocked using 3% Bovine Serum
Albumin (BSA) diluted in PBS containing 0.5% Tween-20 for one hour. The membrane
was incubated overnight at 4°C using anti-OVOL1 antibody (Abcam Ab65023, 1:1000
dilution). The following day, the membrane was washed and incubated with AlexaFluor
Anti-Rabbit 680 nm. Stain-free gel was imaged to detect total protein (control).

2.1.11

Propidium Iodide Staining

After cells are induced in galactose inducing media, three replicates of 200 ul of
each cell culture was added to 1.5 µL tubes. Two additional samples were used as
positive and negative controls. Positive control cells were boiled at 100°C for 15 minutes.
All samples were resuspended in PBS and PI mixture and incubated at room temperature
for 10 minutes. Resuspension solution consisted of 100 µL PBS and 1:200 dilution of
propidium iodide (PI) stock solution (1 mg/mL in H2O). Samples were transferred into a
clear bottom 96-well plate and imaged using Gel Doc system (Biorad). The OD 600nm was
also measured using a plate reader. Percent survival rates were calculated using the
ANALYSR program developed by Chadwick et al4.

2.1.12

Flow Cytometry

Cells were induced overnight in galactose-containing media to induce expression
of mCherry Red Fluorescent Protein tagged protein that contained repeats of glutamine
(polyQ). A BD Bioscience FACS Celesta flow cytometer with a yellow laser at 561 nm
was used to detect red fluorescence. 20,000 cells were analyzed and the median
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fluorescence intensities (MFI) was calculated using BD FACS Diva Software. No gates
were applied during analysis.

2.1.13

Statistical Analysis

Graphpad Prism (La Jolla CA) was used to calculate all statistical analysis of
significance of the Area Under the Curve (AUC) of growth curves was calculated using
the two-tailed unpaired t-test or One-way ANOVA followed by Dunnett’s Multiple
Comparison test. Ct values were calculated using Ct values generated through
quantitative RT-PCR, and two-tailed unpaired t-test was conducted on the 2^Ct
values.
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2.2
2.2.1

Results
Expression of OVOL1 Reduces Yeast Growth

To study OVOL1 function, an OVOL1-yeast model was developed; OVOL1 was
cloned under a GAL1 galactose-inducible promoter into two CEN plasmids with different
auxotrophic markers. One copy (1X-OVOL1) or two copies (2X-OVOL1) of OVOL1
were transformed into yeast and growth assays were conducted to determine whether
OVOL1 elicited a change in phenotype (Fig 2.1). A spot assay was performed where
yeast was serially diluted and pinned onto agar plates with selective media. When 2XOVOL1 was induced, it caused a noticeable decrease in yeast growth, observed by the
lower number of yeast colonies (Fig 2.1). We quantified the decrease in growth by
measuring growth in liquid (Fig 2.1B). Cells with 2 copies of OVOL1 showed a
significant decrease in growth compared to control (Fig 2.1B, C). Since two copies
elicited a change in phenotype, a higher expression model of OVOL1 was used for the
remainder of the project. Western blot analysis was performed to confirm that OVOL1
was being expressed (Fig 2.1D) Indeed only cells expressing 2X-OVOL1 display a band
corresponding to the Ovol1 protein.
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Figure 2.1 OVOL1 expression reduces yeast growth.
Yeast were transfected with either one copy (1X-OVOL1) or two copies (2X-OVOL1) of
Ovol1. Cells were cultured at 30°C in non-inducing media overnight, then were exposed
to inducing media the following day for 24 hrs. Cells were then spotted using a 5-times
serial dilution onto uninduced and induced agar plates for 48 hrs. Yeast with two copies
of OVOL1 caused a growth defect compared to one copy of OVOL1(A). The same cells
were diluted, and growth was measured every 15 minutes for 24 hrs in a Bioscreen.
Growth curves (B) and area under the curve (AUC) (C) was calculated using GraphPad
Prism, and a two-tailed unpaired t–test was performed, non-significant (ns), p ≤ 0.0001
(****). (D) Western blot confirmed expression of 2X-OVOL1. Mean with standard
deviation (SD).
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2.2.2

OVOL1 Causes Cell Cycle Arrest in Yeast
Next, we wanted to confirm that the growth defect caused by OVOL1 is due to

cell death. A propidium iodide stain was performed to determine whether expression of
OVOL1 results in cell death. Cells expressing OVOL1 showed a significant but modest
decrease in percent survival (15% difference) compared to control (Fig 2.2A). Cells
expressing ZnFC2A did not show a difference in percent survival compared to control
(Fig 2.2). This further confirms that OVOL1 requires a functional zinc finger domain to
inhibit growth in yeast. Furthermore, there is no difference in the amount of fluorescence
between PI-stained cells expressing OVOL1, ZnFC2A and control plasmid (Fig 2.2B).
To determine whether these cells are permanently growth arrested or nonviable, we
performed a regrowth assay. After cells have been induced overnight in galactose media
(where OVOL1 is induced), they are spotted onto YPD plates (no OVOL1 induction).
There is no change in the growth of control, OVOL1 and ZnFC2A cells (Fig 2.2C).
Overall, this suggests that the growth defect caused by OVOL1 is due to transient
inhibition of cell growth.
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Figure 2.2 OVOL1 expression does not cause cell death.
Cells expressing wild-type Ovol1 (OVOL1) or zinc finger mutated Ovol1 (ZnFC2A) were
grown in induction media overnight, cells were stained with propidium iodide and
fluorescence was imaged using a Gel Doc system. Percent survival was calculated suing
protocol from Chadwick et al (2016). Positive control (positive) are cells that have been
boiled for five minutes, and the negative control (negative) are cells that have not been
stained with PI. One-way ANOVA followed by Dunnett’s Multiple Comparison test was
performed on GraphPad Prism. OVOL1 caused a significantly lower percent survival than
control, p≤ 0.0001(***), and ZnFC2A cells, p≤ 0.01(**). Mean with SD.

46

2.2.3

OVOL1 Activity is Dependent on Binding to DNA and
HDACs
Yeast cells expressing OVOL1 with the zinc finger mutations (ZnFC2A) showed

no difference in phenotype compared to control when cells are induced in galactose
media (Fig. 2.3A). This confirms that the growth defect is due to OVOL1 having
functional zinc-finger binding activity. OVOL1 also contains an N-terminal 9-amino acid
SNAG domain, which has been implicated in recruiting HDAC15. To determine if the
SNAG domain is required for OVOL1 to suppress yeast growth, we cloned the Δ15OVOL1 plasmid into yeast, and assayed OVOL1’s effect on cell growth. The SNAGdeletion in OVOL1 did not affect growth in wild-type yeast cells (Fig 2.3 A, B). Taken
together, these results suggest that the inhibition of cell growth in yeast is dependent on
zinc finger domain-mediated DNA binding of OVOL1, as well as the SNAG domain.
The requirement of a SNAG domain may indicate that OVOL1 recruits HDACs to genes
implicated in cell growth, thereby deacetylating and repressing these genes.
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Figure 2.3 Mutations in OVOL1 have no effect on yeast growth.
Cells expressing Ovol1 (OVOL1), zinc finger-mutated Ovol1 (ZnFC2A), and SNAGdeleted Ovol1 (Δ15OVOL1) were serially diluted and spotted on glucose (uninduced) and
galactose (induced) plates. Ovol1 mutations did not elicit a growth defect (A). Liquid
growth assay was also performed, and growth curves and area under the curve (AUC)
were generated by GraphPad Prism. Growth was significantly decreased in OVOL1
expressing cells, p≤ 0.01 (**) (B). Mean with standard SD. One-way ANOVA followed
by Dunnett’s Multiple Comparison test using GraphPad Prism.
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2.2.4

Class II HDACs Play a Role in OVOL1 Regulation of Cell
Proliferation
Since HDACs are required for BeWo trophoblast differentiation3, we wanted to

investigate whether OVOL1 requires the presence of HDACs in yeast to regulate cell
proliferation. HDAC deletion strains were used to determine whether there is a genetic
interaction between OVOL1 and HDACs. Initially, three important HDAC proteins from
class I (rpd3Δ), II (hda1Δ) and III (sir2Δ) were used. Growth assays were performed to
determine whether there is a change in growth phenotype. When OVOL1 was induced by
placing cells in galactose media, there was a growth defect evident in control, rpd3Δ and
sir2Δ cells, but no growth defect in hda1Δ (Fig 2.4 A). Furthermore, the other class II
HDAC proteins, hda2 and hda3, also showed a significant rescue in growth compared to
control (Fig 2.5 A).
To further determine whether other HDACs belonging to the three HDAC
families were implicated in regulating cell growth by OVOL1, we transformed OVOL1
constructs into the remaining HDAC deletion strains, and growth assays were performed
(Fig 2.5 and 2.6). Both class I and III showed significant decrease in cellular growth
when OVOL1 was induced, but the growth defect was less pronounced in yeast lacking
class II HDACs (Fig 2.5 and 2.6). Collectively, these results indicate that OVOL1
interacts with class II HDACs to reduce cell growth.
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Figure 2.4 Deletion of HDA1, a class II HDAC, specifically rescues the growth defect
caused by OVOL1.
Control, Ovol1, and ZnFC2A expressing plasmids were transformed into wild-type (WT),
class I (sir2Δ), class II (hda1Δ), and class III (rpd3Δ) HDAC deletion strains. Cell growth
was assessed by serial dilutions onto glucose and galactose plates. hda1Δ expressing
OVOL1 expressing cells rescued the growth defect seen in the other strains expressing
OVOL1 (A). Liquid growth assays were further used to confirm growth rescue, there was
a significant difference in growth between hda1Δ expressing OVOL1 and control cells
expressing a plasmid deficient of OVOL1, p≤0.01 (**) (B). One-way ANOVA followed
by Dunnett’s Multiple Comparison Test.
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Figure 2.5 Deletions of class II HDACs (hda2, hda3) alleviates growth defect caused
by OVOL1.
(A) Spot assay showing wild type strain, class II HDACs (hda2Δ and hda3Δ), and class I
HDACs (hos1Δ and hos2Δ) deletion strains expressing either: control, OVOL1, or
ZnFC2A plasmid. (B) Area under the curve (AUC) was determined by analyzing the
growth curves using GraphPad Prism. Hos1Δ and hos2Δ expressing OVOL1 cells grew
significantly less than wild type (WT) strain, p≤ 0.01(**) and p≤ 0.001(***),
respectively. Class II HDACs, both hda2Δ and hda3Δ cells grew significantly better than
WT OVOL1 cells, p≤ 0.001(***). One-way ANOVA followed by Dunnett’s Multiple
Comparison test. Mean with SD.
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Figure 2.6 Yeast carrying class III HDAC deletions display reduced growth when
OVOL1 is expressed.
(A) Growth assays were performed using wild type and class III HDAC deletions (hst1Δ
hst2Δ, hst3Δ, and hst4Δ) expressing control, OVOL1, or ZnFC2A plasmids. (B) Using
the growth curves generated using a BioScreen Plate Reader, area under the curve (AUC)
was calculated using GraphPad prism, one-way ANOVA followed by Dunnett’s Multiple
Comparison test. Cell growth of hst2Δ, hst3Δ, and hst4Δ is significantly affected, p≤ 0.01
(**), p≤ 0.05 (*). Mean with SD.
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2.2.5

OVOL1 is Expressed in HDA1-Deletion strain
To ensure that our results are not due to reduced OVOL1 expression in yeast

strains lacking class II HDACs, we confirmed that OVOL1 was expressed at the RNA
and protein levels. qRT-PCR was conducted to reveal that OVOL1 is expressed in control
and to even higher extent in hda1Δ cells (Fig 2.7A). Next, a western blot analysis
revealed that OVOL1 protein is present in both the control and hda1Δ strains; however,
reduced protein expression of OVOL1 was evident when the zinc finger domains were
mutated (ZnFC2A) (Fig 2.7 B). OVOL1 was also tagged to a green fluorescent protein
(GFP) reporter to determine cellular localization. We detected OVOL1-ymsfGFP both in
the nucleus and cytoplasm (Fig 2.7 C).
Since hda1Δ strains show a more robust expression of OVOL1, we wanted to test
the GAL1 promoter activity to determine whether it is different between the deletion and
wild-type strain (Fig 2.8). An mCherry-fluorescent reporter under the control of the
GAL1 promoter was transformed into wild-type and hda1Δ strains. Flow cytometry was
performed to determine the level of fluorescence when cells were induced in galactose
media. No change in fluorescence intensity was detected between wild-type and hda1Δ
cells, therefore, the change in OVOL1 mRNA and protein levels cannot be attributed to
different GAL1 driven transcriptional activity (Fig 2.8).
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Figure 2.7 OVOL1 is expressed at both the RNA and protein level in wild type and
hda1Δ cells.
(A) qRT-PCR was conducted to assess the expression of OVOL1. Western blot analysis
(B) was performed to confirm protein expression of OVOL1. (C) Representative
fluorescent microscopy images of control and hda1Δ cells expressing Ovol1-GFP. Please
note the strong nuclear staining in OVOL1-GFP cells.
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Figure 2.8 The GAL1 inducible promoter activity is similar between wild type and
hda1Δ cells.
(A) Wild type and hda1Δ cells expressing an mCherry fluorescence reporter were
analyzed by flow cytometry. (B) Median fluorescent intensity (MFI) of the cells were
calculated from fluorescent data (geometric mean) acquired using flow cytometry. There
was no statistically significant difference in GAL1-promoter activity between wild type
and hda1Δ cells.

58

2.2.6

Ectopically Expressing OVOL1 in Human BeWo trophoblasts
Before determining how overexpressing OVOL1 will affect BeWo trophoblast

proliferation, we wanted to ensure BeWo cells are able to upregulate differentiation
markers in the presence of cAMP. OVOL1 and ERVFRD1 are trending towards an
increase in expression, and CGB shows a significant increase in expression in cells
treated with cAMP compared to control cells (Fig 2.9). However, there was no significant
change in expression of TP63, which is a stem cell associated gene (Fig 2.9). BeWo cells
maybe be undergoing differentiation under induction media; however, more replicates are
required. We then used BeWo cells to determine the effect of ectopically overexpressing
OVOL1 on trophoblast differentiation. To develop such a model, I cloned OVOL1 into a
pEF-GFP vector. qRT-PCR was performed to detect increased expression of OVOL1
mRNA levels in cells transfected with the pEF-OVOL1 vector (Fig 2.10). BeWo cells
exhibited a significant increase in OVOL1 expression compared to control cells, along
with an increase in expression of a differentiation-associated transcript, ERVFRD-1 (Fig
2.10). Lastly, expression of CGB, a hormone produced by syncytiotrophoblast, increased
when OVOL1 protein is overexpressed compared to control cells (Fig 2.10). Thus,
ectopic expression of OVOL1 maybe sufficient to drive cells to undergo at least partial
differentiation by increasing expression of syncytial-associated genes.
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Figure 2.9 Treatment of BeWo Trophoblast with cAMP upregulates genes
associated with differentiation.
BeWo cells were either untreated (Ctrl) or treated with 10 µL/ng of cAMP (+cAMP) for
48 hrs before cells were lysed and RNA was isolated. qRT-PCR was conducted to
determine expression levels of OVOL1, the cytotrophoblast marker TP63, and the
syncytiotrophoblast-associated genes CGB and ERVFRD-1. Expression of the following
markers was significantly increased in cAMP treated cells: OVOL1 (p≤0.01,**),
ERVFRD-1 (p≤0.001,***) and CGB (p≤0.0001,****). Unpaired t-test was conducted
using Graphpad Prism. Mean with SD. N= 3.
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Figure 2.10 Ectopic expression of OVOL1 partially drives expression of genes
associated with differentiation in BeWo cells.
BeWo cells were transfected with pEF-GFP plasmid (Ctrl) or pEF-OVOL1 (Ovol1). Cells
were lysed for RNA and qRT-PCR was used to detect expression of Ovol1, ERVFRD-1,
CGB and TP63. Using GraphPad Prism, significance was determined using an unpaired ttest. Cells overexpressing Ovol1 has significantly more OVOL1 and ERVFRD-1
expression under 10 µL/ng of cAMP (p≤0.05), There was no significance expression of
CGB and TP63 between ctrl and OVOL1 overexpressing cells. Mean with SD. N= 3.
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2.1

Discussion

The world faced a pandemic that affected research across the world. Due to university
closures, my work in BeWo cells had to come to a halt unexpectedly. I will list the
remaining experiments that were needed to complete my thesis. To confirm that
overexpression of OVOL1 is sufficient to cause cell fusion and increase of expression of
syncytial-associated genes first, a few more replicates are needed to ensure that
ectopically overexpressing OVOL1 in BeWo trophoblasts is correlated with increased
gene expression of ERVFRD-1 and CGB. Immunofluorescence experiments would be
conducted on BeWo trophoblasts with OVOL1 overexpression to look at percent fusion.
Fluorescent-labeled antibodies targeting hCGB and CDH1 (or Actin) will be used to look
at cellular fusion, and cells will be counted to determine percent fusion occurring
compared to cells transfected with a control plasmid.
Second, to determine whether HDAC function is required for OVOL1 to induce
differentiation. OVOL1 will be overexpressed, and one HDAC protein from class II
family will be targeted at a time using siRNA. Western blot analysis will be used to
confirm downregulation of class II HDACs, qRT-PCR to determine whether ERVFRD-1
and CGB are upregulated under OVOL1 overexpression in the absence of class II
HDACs, and immunofluorescent to observe cell fusion.
Lastly, co-immunoprecipitation assay would be conducted to determine whether class
II HDAC protein directly interacts with OVOL1, and RNA-seq would be used to
determine expression of genes that are altered during overexpression of OVOL1.
My work is the first to use yeast Saccharomyces cerevisiae to investigate how
OVOL1 affects cell proliferation. Yeast have been widely used to model human genes
and assess protein functionality and their effect on cell growth 6. The absence of an
OVOL1 homolog makes yeast an attractive model to study the phenotype associated with
OVOL1expression on growth and proliferation. Thus, we used yeast to study the effect of
OVOL1 on cell growth. When trophoblasts differentiate, they increase expression of
OVOL1 which redirects cells from a proliferating to a differentiating state, which is
associated with activation of genes that promote differentiation (ERVFDR-1 and CGB)
and repression of proliferation-associated genes (TP63) 7. It was interesting that ectopic
expression of OVOL1 in yeast caused reduced cell growth and provides further evidence
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that the primary function of OVOL1 in differentiating cells is the repression of
proliferation. OVOL1 has been characterized to transcriptionally represses genes through
two processes; indirectly repressing gene expression by recruiting co-repressors or by
directly binding to promoters upstream of target genes 5,8. OVOL1 was able to repress the
OVOL1 promoter by binding to a specific target sequence, CCGTTA, and recruit HDACs
to OVOL1 promoter to cause gene repression 5. How OVOL1 interacts with histone
deacetylase complexes, and whether this interaction is important for the regulation of cell
growth, has yet to be determined. We wanted to investigate HDAC-OVOL1 relationship
with regards to cellular growth. Therefore, we predicted that histone deacetylase
complexes may be acting with OVOL1 to regulate cellular proliferation and growth in
yeast.
Since OVOL1 causes a growth defect in yeast, we determined whether the absence of
HDACs can rescue growth. Using some HDAC deletion strains from a deletion library,
we cloned the OVOL1 gene into class I, II and III HDAC deletion strains to determine
whether there is an underlying genetic interaction between HDACs and OVOL1. We
found that deletion of class II HDACs alleviated the growth defect induced by OVOL1.
In addition, there was a difference in the degree of rescue between the three HDACs
within class II. Hda2Δ and hda1Δ significantly mitigated the growth defect caused by
OVOL1 expression compared to hda3Δ. The difference in level of growth may be due to
a number of reasons.
First, class II HDACs work together by forming a tetrameric complex to deacetylate
histones and share similar genetic interactions9,10. Therefore, if one of the HDAC proteins
is absent from the complex, it could render the complex unable to optimally remove
acetyl groups from histones. Second, each subunit within the class II HDAC complex has
unique genetic interactions and function in different cellular pathways; only 7% of
interactions are shared amongst the three proteins when a genome wide screen was
conducted in yeast 11. For example, HDA2 plays a bigger role in peroxisome function and
maintenance than the other two class II HDACs, it also interacts with the HDAC complex
by directly binding to HDA3 12. HDA3 is important in nuclear/cytoplasmic transport, and
directly interacts with HDA1 11,12. HDA1 interaction with HDA2-HDA3 subunit is
necessary because HDA2 has a prosthetic group involved in transferring an acetyl group
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during histone deacetylation, and HDA3 is important in bringing the subcomplex HDA2HDA3 with HDA1 homodimer 12,13. Both HDA2-HDA3 are essential because they are
important in histone recognition and altering HDA1 stoichiometry thereby activate the
catalytic subunit found in the HDA1 protein 12. Similar to yeast class II protein
interaction, human class II HDACs show analogous interactions within a multiprotein
complex 14.
Overall, our data suggest that class II HDACs are necessary for OVOL1 to inhibit
cellular proliferation. Interestingly, class II HDACs seem to play a role in regulating
activity of pivotal transcription factors during trophoblastic fusion 15. Inhibiting HDACs
in BeWo trophoblasts prevented their fusion and differentiation into syncytiotrophoblast
3.

Therefore, HDACs may be necessary in regulating placental development and the

integrity of the placental exchange surface.
When HDA1 is deleted in yeast, OVOL1 protein levels decrease compared to
wild-type cells; OVOL1 protein level is further reduced when the DNA binding region is
mutated. Since OVOL1 expression levels remained unchanged between OVOL1 and
ZnFC2A, our data suggests that in order for OVOL1 to function, it needs to be stabilized
by binding to HDA1. Thus, in the absence of HDA1 and when the zinc finger domain is
mutated there is a decrease in OVOL1 and ZnFC2A protein levels. Protein stabilization
by HDACs is similarly observed with other transcription factors such as HIF1𝛼 and with
class III HDACs like SIRT1. SIRT1 directly binds to HIF1𝛼 to deacetylate and stabilize
it during hypoxia, which mediates increase in genes promoting cancer cell invasion 16,17.
Histone deacetylase complexes can also deacetylate non-histone proteins such as
transcription factors, which can act to stabilize or destabilize them. Human HDAC 1, 3, 4
and 5 (HDAC 4 and 5 are class II HDACs) are expressed throughout the placenta, and
during trophoblast cell fusion, they act to deacetylate glial cell missing homolog 1
(GCM-1) to destabilize it and inactivate it15. Class II HDACs have been shown to be
essential in regulating trophoblast differentiation, invasion and migration. Chang et al.
found that when cytotrophoblast cells are induced to differentiation, syncytiotrophoblast
cells had increased expression levels of HDAC5 and GCM-1, and both had increased
colocalization in the nucleus. HDAC5 can also be phosphorylated, which causes it to be
exported outside of the nucleus and thereby prevented from altering gene expression and
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preventing excessive fusion18. Similarly, HDAC9 is localized in the nucleus of
syncytiotrophoblast and is critical for trophoblast invasion and migration during early
stages of blastocyst implantation19. It does so by repressing expression of a matrix
metalloproteinase inhibitor (TIMP3), thereby allowing matrix metalloproteinases
(MMPs) to degrade and remodel the decidua to facilitate for further blastocyst invasion 19.
Interestingly, HDAC5 is downregulated in preeclamptic placentas 19. Lastly, HDAC5 is
important in regulating EMT switch in trophoblast cells during implantation20. In
addition, I have shown that class II HDACs function and genetic interaction with OVOL1
is important for cellular proliferation.
We found that ERVFRD-1 expression increased when OVOL1 was overexpressed
in BeWo cells. Since inhibiting HDACs reduces BeWo cell differentiation3, it is possible
that HDACs may be regulating OVOL1 protein levels through post translational
modification by deacetylating OVOL1 and rendering it active. Therefore, OVOL1 may
be unstable when the zinc finger domain is mutated or when it is being acetylated (in the
absence of HDA1).
Elevated OVOL1 levels in trophoblast cells is associated with terminal
differentiation into syncytiotrophoblast and its mechanism of action is not well explored.
In order for trophoblasts to differentiate they require transcription factors to turn off
genes involved in proliferation. Our yeast findings indicate a genetic interaction between
class II HDACs and OVOL1. We believe that OVOL1-HDAC regulation of cellular
growth and proliferation in yeast is similar in BeWo trophoblasts.
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2.2

Conclusion

The next steps to determine overexpression of OVOL1 in BeWo trophoblast cells
was to conduct experiments that determined whether overexpression of OVOL1 was
sufficient to induce differentiation in trophoblast cells in the absence of specific HDAC
proteins. To determine whether HDACs are required for differentiation, we can use TSA
to block HDAC activity or siRNA to knockdown specific HDACs in conjunction with
overexpressing OVOL1. CRISPR Screen can be conducted to identify genes which can
help define the role of OVOL1 and the cellular pathway it acts through. RNA Sequencing
(RNA-Seq) can also be used to determine change in transcript levels of genes involved in
differentiation under OVOL1 overexpression.
Nair et al.5 and Renaud et al.7 both found that OVOL1 represses gene expression
by binding to a conserved sequence, CCGTTA, within the promoter regions of genes like
MYC and ID2. We can perform a chromatin immunoprecipitation (ChIP) assay on BeWo
trophoblasts that have ectopic overexpression of OVOL1 in the absence of HDACs. This
will allow us to answer questions like: Will OVOL1 still bind to CCGTTA of genes
involved in cell proliferation in the absence of HDACs? Can OVOL1 directly or
indirectly (through HDACs or HATs) regulate expression of differentiation-associated
genes like ERVFRD-1? When the DNA binding region is mutated, OVOL1 was unable to
rescue the growth defect seen in yeast. We can use a similar experiment in BeWo cells to
determine whether the zinc finger region is necessary when OVOL1 is overexpressed.
We believe that cellular proliferation and differentiation is regulated by OVOL1
and HDAC proteins interacting to regulate gene expression. In order to determine
whether OVOL1 exclusively binds to class II HDACs, we perform a
immunoprecipitation (IP) assay to determine whether OVOL1 binds specific class II
HDACs or to other classes of HDACs in BeWo trophoblasts to cause gene repression.
Protein-protein interaction can also be examined using Fluorescence Resonance Energy
Transfer (FRET) or Split-Ubiquitin Yeast Two Hybrid (Split-Ubi) assay.
HDACs modify acetylation on histone proteins, to determine which acetylation
sites are affected, mass spectrometry is a great tool to determine the sites of acetylation
and whether acetylation levels change when OVOL1 is overexpressed independent of
HDAC inhibition or with class II HDAC inhibition. HDACs also regulate activity of
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non-histone proteins, and by performing mass spectrometry we can determine whether
lysine sites on OVOL1 and other proteins are deacetylated during BeWo trophoblast
differentiation.
Future work will investigate whether OVOL1 is directly recruiting class II
HDACs to promoter regions of DNA involved in cellular growth and proliferation. If
OVOL1 proteins are not stabilized by HDAC binding, the proteins could be quickly
degraded and cell growth will not be affected . Since protein degradation is highly
conserved across eukaryotes, including in yeast. We can inhibit proteasomes and HDAC
activity in yeast and BeWo cells to determine the protein turnover rate of OVOL1, and
whether that affects both cellular proliferation and differentiation. We can perform a
cycloheximide (CHX)-chase assay in BeWo cells. Cells will be collected after addition of
CHX and cAMP after certain time points for 48 hrs to determine the level of OVOL1
present in cells that are differentiating. We can also inhibit HDAC function by using TSA
and then measure OVOL1 protein turnover rate. Experiments such as CHX-chase assays
will help determine whether stability of OVOL1 is important in its function.
Regulating trophoblast proliferation and differentiation is critical for the
maintenance of the fetal-maternal barrier in the placenta. Furthermore, OVOL1 is not
only important in placental-related diseases, but it is also important in regulating cell
growth in cancers involving many types of epithelial cells. OVOL1 acts downstream of
signaling pathways involved in regulating the mesenchymal-to-epithelial transition
(MET) in prostate and breast cancer, and squamous cell carcinoma. OVOL1 represses
ZEB1 (an inducer in epithelial to mesenchymal transition), and works with transcription
factors such as AP1, STAT1, STAT3 and NFKB1 to regulate MET 21,22. Overall, our
findings validate our hypothesis that OVOL1 regulates cellular proliferation through its
interaction with class II HDACs (diagram of hypothetical model explained in Fig 2.11).
Our findings in yeast help us understand the underlying mechanisms through which
OVOL1 acts and adds to the repertoire of work done in many other model organisms.
Future work is needed to better delineate OVOL1 interactions and transcription
regulation in mammalian epithelial development. These discoveries will provide insight
into the mechanisms through which OVOL1 acts to repress gene expression and enhance
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our fundamental understanding of placental biology and in producing therapeutic targets
for cancer/disease treatments.
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Figure 2.11 Hypothetical Model Underlying OVOL1 Transcriptional Regulation.
We hypothesize that OVOL1 is able to repress genes necessary for cellular proliferation.
OVOL1 recruits class II HDACs through its SNAG domain (1). Using OVOL1’s zinc
finger region, it is able to bind to DNA thereby causing deacetylation and remodelling the
chromatin (2) into a more condensed state. This state prevents transcription factors and
other transcription-driving machinery from accessing the promoter of target genes,
thereby causing gene repression (3).
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